Abstract
Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Current Pharmaceutical Design
Title:How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease
Volume: 23 Issue: 31
Author(s): Salvatore Santo Signorelli*
Affiliation:
- Department of Clinical and Experimental Medicine, University of Catania; General Medicine Division, University Hospital “G.Rodolico. Catania,Italy
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Abstract: Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Export Options
About this article
Cite this article as:
Signorelli Santo Salvatore*, How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170608083605
DOI https://dx.doi.org/10.2174/1381612823666170608083605 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lifestyle Modifications in the Treatment of Hypertension
Current Hypertension Reviews Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued) Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Cell-free Nucleic Acids as a Non-Invasive Route for Investigating Atherosclerosis
Current Pharmaceutical Design p38 MAP Kinase Mediated Proteoglycan Synthesis as a Target for the Prevention of Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Reverse Induced Fit-Driven MAS-Downstream Transduction: Looking for Metabotropic Agonists
Current Medicinal Chemistry Quality Control of Fingerprint of Radix Astragali by High-Performance Liquid Chromatography Coupled with Chemometric Methods
Current Pharmaceutical Analysis Genes and Hypertension
Current Pharmaceutical Design Determinants of Human Coronary Collaterals
Current Cardiology Reviews The Autocrine/Paracrine Loop After Myocardial Stretch: Mineralocorticoid Receptor Activation
Current Cardiology Reviews Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
Current Vascular Pharmacology Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling
Current Hypertension Reviews Integrative Control of Gastrointestinal Motility by Nitric Oxide
Current Medicinal Chemistry Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Roles of Perilipins in Diseases and Cancers
Current Genomics Fenoldopam in Cardiovascular Surgery: A Review
Vascular Disease Prevention (Discontinued) Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology